The drug candidate is currently in clinical phase II under the EU financed NEMO (Treatment of NEonatal seizures with Medication Off-patent project).
Under the collaboration, O4CP will be responsible for obtaining market authorizations and for manufacturing of drug product.
Sobi will take charge of commercialization of the product on a global basis.
The deal involves an upfront payment by Sobi in the amount of 300 000 Euro and potential future milestones of a value up to approximately 1.7m Euro.
O4CP will also receive royalties on future commercial sales.